KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Depreciation & Amortization: 2011-2025

Historic Accumulated Depreciation & Amortization for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $500,000.

  • Supernus Pharmaceuticals' Accumulated Depreciation & Amortization fell 16.67% to $500,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 million, marking a year-over-year decrease of 7.79%. This contributed to the annual value of $80.4 million for FY2024, which is 5.24% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Accumulated Depreciation & Amortization is $500,000, which was down 0.00% from $500,000 recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $21.7 million during Q4 2023, and its lowest value of $500,000 during Q2 2025.
  • In the last 3 years, Supernus Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $600,000 in 2024 and averaged $9.6 million.
  • In the last 5 years, Supernus Pharmaceuticals' Accumulated Depreciation & Amortization spiked by 1,218.40% in 2021 and then dropped by 25.00% in 2023.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Accumulated Depreciation & Amortization stood at $12.7 million in 2021, then surged by 64.07% to $20.8 million in 2022, then grew by 3.97% to $21.7 million in 2023, then declined by 13.06% to $18.8 million in 2024, then dropped by 16.67% to $500,000 in 2025.
  • Its Accumulated Depreciation & Amortization stands at $500,000 for Q3 2025, versus $500,000 for Q2 2025 and $20.4 million for Q1 2025.